Romi Gupta

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 23

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Cell death & disease

Journal of translational medicine

Oncogene

The University of Alabama

Max Planck Institute for Molecular Genetics (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The University of Alabama Jun 01 2019

United States

Assistant Professor :: Biochemistry and Molecular Genetics

Education History

Max Planck Institute for Molecular Genetics Apr 15 2006 - Dec 15 2009

Germany

PHD :: Ribosome group

Publications

Praveen Guruvaiah, Romi Gupta
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers. Journal of translational medicine 22 (1) (2024)
Kiran Kumar Reddi, Suresh Chava, Siva Chander Chabattula, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability. Cell death & disease 15 (6) (2024)
Kiran Kumar Reddi, Suresh Chava, Siva Chander Chabattula, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability. Cell death & disease 15 (6) (2024)
Kiran Kumar Reddi, Suresh Chava, Siva Chander Chabattula, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability. Cell death & disease 15 (6) (2024)
Praveen Guruvaiah, Romi Gupta
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers. Journal of translational medicine 22 (1) (2024)
Kiran Kumar Reddi, Suresh Chava, Siva Chander Chabattula, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability. Cell death & disease 15 (6) (2024)
Praveen Guruvaiah, Romi Gupta
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers. Journal of translational medicine 22 (1) (2024)
Suresh Bugide, Yvonne J K Edwards, Romi Gupta, Michael R Green, Narendra Wajapeyee
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (4) (2023)
Suresh Bugide, Yvonne J K Edwards, Romi Gupta, Michael R Green, Narendra Wajapeyee
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (4) (2023)
Suresh Bugide, Yvonne J K Edwards, Romi Gupta, Michael R Green, Narendra Wajapeyee
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (4) (2023)
Suresh Bugide, Yvonne J K Edwards, Romi Gupta, Michael R Green, Narendra Wajapeyee
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (4) (2023)
Praveen Guruvaiah, Suresh Chava, Chiao-Wang Sun, Nirupama Singh, Courtney A Penn, Romi Gupta
ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE. Cell death & disease 14 (7) (2023)
Suresh Bugide, Yvonne J K Edwards, Romi Gupta, Michael R Green, Narendra Wajapeyee
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (4) (2023)
Suresh Bugide, Yvonne J K Edwards, Romi Gupta, Michael R Green, Narendra Wajapeyee
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (4) (2023)
Romi Gupta
Epigenetic regulation and targeting of ECM for cancer therapy. American journal of physiology. Cell physiology 322 (4) (2022)
Roshan Dutta, Praveen Guruvaiah, Kiran Kumar Reddi, Suresh Bugide, Dhana Sekhar Reddy Bandi, Yvonne J K Edwards, Kamaljeet Singh, Romi Gupta
UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. NAR cancer 4 (4) (2022)
Suresh Chava, Suresh Bugide, Yvonne J K Edwards, Romi Gupta
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. Oncogenesis 10 (7) (2021)
Narendra Wajapeyee, Romi Gupta
Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies. Cancer research 81 (22) (2021)
Suresh Bugide, Romi Gupta, Michael R Green, Narendra Wajapeyee
EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 118 (30) (2021)
Vipin Rawat, Parmanand Malvi, Deborah Della Manna, Eddy Shih-Hsin Yang, Suresh Bugide, Xuchen Zhang, Romi Gupta, Narendra Wajapeyee
PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1. Oncogene 40 (13) (2021)
Romi Gupta, Radoslav Janostiak, Narendra Wajapeyee
Transcriptional regulators and alterations that drive melanoma initiation and progression. Oncogene 39 (48) (2020)
Romi Gupta, Parmanand Malvi, Keshab Raj Parajuli, Radoslav Janostiak, Suresh Bugide, Guoping Cai, Lihua Julie Zhu, Michael R Green, Narendra Wajapeyee
KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity. Proceedings of the National Academy of Sciences of the United States of America 117 (22) (2020)
Parmanand Malvi, Radoslav Janostiak, Suresh Chava, Padmini Manrai, Esther Yoon, Kamaljeet Singh, Malini Harigopal, Romi Gupta, Narendra Wajapeyee
LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis 9 (8) (2020)

Romi Gupta.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Romi Gupta